Article Text

Download PDFPDF

PO.5.105 The effect of belimumab on extra-renal outcomes: results from the phase 3, randomised, placebo-controlled, 104-week bliss-ln study in patients with active lupus nephritis
  1. J Weinmann-Menke1,
  2. M Okada2,
  3. C Arriens3,
  4. A Jones-Leone4,
  5. RA Levy4,
  6. JA Gilbride5,
  7. R Furie6 and
  8. N Yang7
  1. 1University Medical Center Mainz, Johannes Gutenberg University Mainz ~ Mainz ~ Germany
  2. 2St. Luke’s International Hospital, Immuno-Rheumatology Center ~ Tokyo ~ Japan
  3. 3Oklahoma Medical Research Foundation, Arthritis and Clinical Immunology ~ Oklahoma City ~ USA
  4. 4GlaxoSmithKline, Global Medical Affairs ~ Collegeville ~ USA
  5. 5GlaxoSmithKline, RandD Biostatistics ~ Stevenage ~ UK
  6. 6Northwell Health, Division of Rheumatology ~ Great Neck ~ USA
  7. 7First Affiliated Hospital, Department of Rheumatology, Sun Yat-sen University ~ Guangzhou ~ China


Purpose The effect of belimumab (BEL) on renal outcomes has been previously demonstrated in the BLISS-LN study in patients with active lupus nephritis (LN).1 Here we evaluate the effect of BEL on pre-specified extra-renal outcomes in patients with LN enrolled in the BLISS-LN study.

Methods In this Phase 3, double-blind, placebo (PBO)-controlled study (GSK Study BEL114054; NCT01639339), adult patients with systemic lupus erythematosus (SLE) and biopsy-proven LN (class III, IV, and/or V) were randomised (1:1) to monthly intravenous (IV) BEL 10 mg/kg or PBO, plus standard therapy (ST). Randomisation was stratified by race and treatment regimen (high-dose corticosteroids + either cyclophosphamide followed by azathioprine, or mycophenolate mofetil [MMF] followed by MMF). Primary and major secondary efficacy endpoints and safety have been previously published.1 Extra-renal efficacy endpoints included: change from baseline in SLE Disease Activity Index-2000 (SLEDAI-S2K; excluding renal items); proportion of patients with SLEDAI-S2K organ system improvement (excluding renal involvement); proportion of patients with Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) worsening; and proportion of patients with prednisone-equivalent dose ≤7.5mg/day and ≤5 mg/day at Week 104.

Results Overall, 448 patients were randomised and received study treatment (safety population: n=224/treatment group; modified intention-to-treat [mITT] population: n=223/treatment group). In total, 91 (20.4%) patients withdrew from the study, mainly due to withdrawal of consent (10.1%). The mean (standard deviation [SD]) SLEDAI-S2K score at baseline was 12.3 (5.0) and mean (SD) SDI score was 0.4 (1.0). Most patients (86.1%) had immunologic SLEDAI-S2K involvement at baseline and 39.2% had mucocutaneous involvement (rash, n=119 [26.7%]; alopecia, n=101 [22.6%]; mucosal ulcers, n=29 [6.5%]). At Week 104, there was a significantly greater change from baseline in SLEDAI-S2K (excluding renal items) in the BEL group than in the PBO group (treatment difference vs PBO [95% confidence interval]: –0.4 [–0.8, 0.0]; p=0.0436; Table 1). Among patients with organ system involvement at baseline, at Week 104, greater proportions of BEL-treated patients versus PBO-treated patients had improvements from baseline in the immunologic, cardiovascular/respiratory and vascular SLEDAI-S2K domains, while improvements in mucocutaneous, musculoskeletal and hematologic domains favoured PBO (Table 1). At Week 104, numerically more PBO-treated patients (7.8%) than BEL-treated patients (6.5%) experienced SDI worsening while on treatment (p=0.7293; Table 1). At Week 104, significantly more BEL-treated patients versus PBO-treated patients were receiving average prednisone-equivalent doses of ≤7.5 and ≤5.0 mg/day (p=0.0139 and p=0.0444, respectively; Table 1).

Abstract PO.5.105 Table 1

Summary of extra-renal efficacy outcomes at weeks 104 (mITT population)

Conclusions The 104-week BLISS-LN study demonstrated that some extra-renal outcomes and steroid dose reduction favoured BEL, compared with ST alone in patients with active LN.


  1. Furie R, et al. N Engl J Med 2020;383:1117–28.

Funding GSK.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.